Recent News

• 03.31.2026 - Biogen to Acquire Apellis, Enhancing the Company’s Growth Portfolio in Immunology and Rare Disease, Bolstering Growth Outlook and Accelerating Expansion into Nephrology
• 03.30.2026 - FDA Approves New High Dose Regimen of SPINRAZA® (nusinersen) for Spinal Muscular Atrophy
• 03.28.2026 - Biogen Announces Second Positive Phase 2 Litifilimab Trial in Cutaneous Lupus Erythematosus at 2026 American Academy of Dermatology Annual Meeting, Showing a Significant Reduction in Skin Disease Activity
• 03.20.2026 - Results from Real-World, Long-Term Treatment Persistence with LEQEMBI® (lecanemab-irmb) in the United States Presented at AD/PD™ 2026
• 03.19.2026 - Biogen to Present New Late-Breaking Litifilimab Phase 2 AMETHYST Data in Cutaneous Lupus Erythematosus at 2026 American Academy of Dermatology Annual Meeting
• 03.11.2026 - Biogen Presents Additional Salanersen Data Showing New Motor Milestones Achieved in Children with SMA Previously Treated with Gene Therapy
• 03.05.2026 - Biogen to Share New SMA Data at Muscular Dystrophy Association and SMA Europe Conferences
• 03.04.2026 - The New England Journal of Medicine Publishes First Data to Demonstrate the Potential for Disease Modification in Dravet Syndrome

Recent Filings

• 03.26.2026 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 03.11.2026 - 8-K Current report
• 02.17.2026 - 4 Statement of changes in beneficial ownership of securities
• 02.17.2026 - 4 Statement of changes in beneficial ownership of securities
• 02.17.2026 - 4 Statement of changes in beneficial ownership of securities
• 02.17.2026 - 4 Statement of changes in beneficial ownership of securities
• 02.17.2026 - 4 Statement of changes in beneficial ownership of securities
• 02.17.2026 - 4 Statement of changes in beneficial ownership of securities
• 02.17.2026 - 4 Statement of changes in beneficial ownership of securities
• 02.17.2026 - 4 Statement of changes in beneficial ownership of securities